Inventor · disambiguated record
Takaji Wakita
Also filed as: WAKITA TAKAJI
24 granted patents·7 pending applications·122 citations·filing 1997–2019
94Inventor score
Files withWAKITA TAKAJI11GEN HOSPITAL CORP3TOKYO METROPOLITAN ORG MED RES3TORAY INDUSTRIES3TANABE JUN-ICHI2
Top patents by PatentIndex Score
31 records- 0186US7935676B2Nucleic acid construct containing a nucleic acid derived from the genome of hepatitis C virus (HCV) of genotype 2A, and a cell having such nucleic acid construct introduced thereinTORAY INDUSTRIES·Filed 2003·Granted May 3, 2011·14 cites·18 claims
- 0285US8592559B2Antibody having activity of inhibiting hepatitis C virus (HCV) infection and use thereofWAKITA TAKAJI·Filed 2010·Granted Nov 26, 2013·6 cites·5 claims
- 0384US6235888B1Hepatitis C virus vaccineGEN HOSPITAL CORP·Filed 1997·Granted May 22, 2001·60 cites·6 claims
- 0482US7659103B2Nucleic acid construct containing fulllength genome of human hepatitis C virus, recombinant fulllength virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis C virus ParticleTOKYO METROPOLITAN ORG MED RES·Filed 2005·Granted Feb 9, 2010·7 cites·20 claims
- 0579US6831169B2Hepatitis C virus vaccineGEN HOSPITAL CORP·Filed 2001·Granted Dec 14, 2004·8 cites·9 claims
- 0675US8183044B2Recombinant human hepatitis C virus-like particle and method for producing the sameTANABE JUN-ICHI·Filed 2006·Granted May 22, 2012·2 cites·10 claims
- 0775US8143022B2High production system for infectious hepatitis C virus particleTANABE JUN-ICHI·Filed 2006·Granted Mar 27, 2012·2 cites·5 claims
- 0873US8604179B2Nucleic acid comprising chimeric gene derived from hepatitis C virusAKAZAWA DAISUKE·Filed 2009·Granted Dec 10, 2013·2 cites·15 claims
- 0968US8993228B2Antibody binding to envelope protein 2 of hepatitis C virus and method for identifying genotype of hepatitis C virus using the sameWAKITA TAKAJI·Filed 2009·Granted Mar 31, 2015·1 cites·5 claims
- 1063US8460912B2Nucleic acid construct containing full length genome of human hepatitis C virus, recombinant full length virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis C virus particleWAKITA TAKAJI·Filed 2009·Granted Jun 11, 2013·0 cites·5 claims
- 1161US8754061B2Nucleic acid construct containing a nucleic acid derived from the genome of hepatitis C virus (HCV) of genotype 2a, and a cell having such nucleic acid construct introduced thereinTORAY INDUSTRIES·Filed 2013·Granted Jun 17, 2014·0 cites·11 claims
- 1260US6429355B1Hepatitis C animal modelTOKYO METROPOLITAN INST OF MED·Filed 2000·Granted Aug 6, 2002·5 cites·3 claims
- 1357US2014046034A1Antibody having activity of inhibiting hepatitus c virus (hcv) infection and use thereofJP NAT INST INFECTIOUS DISEASE·Filed 2013·Application pending·0 cites
- 1456US8383371B2Nucleic acid construct containing a nucleic acid derived from the genome of hepatitis C virus (HCV) of genotype 2a, and a cell having such nucleic acid construct introduced thereinTORAY INDUSTRIES·Filed 2010·Granted Feb 26, 2013·0 cites·3 claims
- 1555US6201166B1Transgenic mouse hepatitis C virus model comprising a hepatitis C viral fragmentTOKYO METROPOLITAN INST OF MED·Filed 1997·Granted Mar 13, 2001·8 cites·1 claims
- 1654US8834893B2Nucleic acid derived from hepatitis C virus and expression vector, transformed cell, and hepatitis C virus particles each prepared by using the sameWAKITA TAKAJI·Filed 2009·Granted Sep 16, 2014·0 cites·19 claims
- 1754US7790448B2Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said geneTOKYO METROPOLITAN ORG MED RES·Filed 2007·Granted Sep 7, 2010·0 cites·11 claims
- 1851US8022197B2Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said geneTOKYO METROPOLITAN ORG MED RES·Filed 2004·Granted Sep 20, 2011·0 cites·9 claims
- 1949US9234184B2Nucleic acid construct comprising nucleic acid derived from genome of hepatitis C virus of genotype 1B, hepatitis C virus genome-replicating cells transfected with the same, and method for producing infectious hepatitis C virus particlesWAKITA TAKAJI·Filed 2012·Granted Jan 12, 2016·0 cites·19 claims
- 2049US9175269B2Modified human hepatitis C virus genomic RNA that can be autonomously replicatedTOKYO METROPOLITAN INST MEDICAL SCIENCE·Filed 2013·Granted Nov 3, 2015·0 cites·12 claims
- 2149US2010291545A1Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereofWAKITA TAKAJI·Filed 2008·Application pending·0 cites
- 2249US2010278865A1Production and use of epitope-tagged hepatitis c virus particleWAKITA TAKAJI·Filed 2008·Application pending·0 cites
- 2348US8454973B2Modified human hepatitis C virus genomic RNA that can be autonomously replicatedWAKITA TAKAJI·Filed 2005·Granted Jun 4, 2013·0 cites·10 claims
- 2444US2021061859A1NTCP InhibitorUNIV TOKYO·Filed 2019·Application pending·0 cites
- 2539US6025341AChimeric hepatitis B/hepatitis C virus vaccineGEN HOSPITAL CORP·Filed 1997·Granted Feb 15, 2000·7 cites·60 claims
- 2635US9186383B2Mutant replicon derived from genome of hepatitis C virus J6CF strainWAKITA TAKAJI·Filed 2012·Granted Nov 17, 2015·0 cites·12 claims
- 2734US9057048B2Infectious hepatitis C virus—high producing HCV variants and use thereofKITAMURA YOSHIHIRO·Filed 2011·Granted Jun 16, 2015·0 cites·10 claims
- 2831US9453056B2Nucleic acid construct comprising nucleic acid derived from genome of hepatitis C virus of genotype 3aWAKITA TAKAJI·Filed 2012·Granted Sep 27, 2016·0 cites·12 claims
- 2931US2012251572A1Hepatitis c virus vaccine compositionWAKITA TAKAJI·Filed 2010·Application pending·0 cites
- 3030US2017107273A1Antibody having infection-inhibiting activity against hepatitis c virusJAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NAT INST OF INFECTIOUS DISEASES·Filed 2015·Application pending·0 cites
- 3128US2015258189A1Hepatitis c virus particles formation promoter, and method of producing hepatitis c virus particlesNAT UNIV CORP UNIV KOBE·Filed 2013·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →